Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression.
Atherosclerosis is an example of a complex trait, where the course of the disease is influenced by a combination of common variation in a constellation of genes and the effect of a wide range of environmental variables. Thus, the underlying disease mechanisms will be modulated by genetic diversity and the effect this diversity has on an individual's response to environmental challenges such as smoking, diet, and exercise. Unlike the consequences of mutations in severe single-gene disorders on protein function, the impact of individual common, functionally important sequence changes in genes contributing to multifactorial diseases is likely to be very small. The challenge is to dissect the contribution that each of these genes makes to the disease process. We have tackled this by identifying common genetic variants, studying their effects on function, and applying them to the analysis of association in appropriately structured and suitably powered studies. Even with our incomplete understanding of the disease, the list of potential candidate genes we could study is vast; but, we do know from pathological studies that a wide spectrum of structural architecture exists in atherosclerotic plaques, suggesting that remodeling of vascular connective tissue is fundamentally important. Matrix remodeling is controlled by a complex network of cell and matrix interactions, the net outcome of which is the product of a balance between synthetic and degradative processes. Our work has focused on the family of enzymes and inhibitors most directly associated with matrix turnover--the matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs, tissue inhibitors of MPs). We specifically searched for functionally relevant genetic variants that might modulate the delicate control of matrix turnover. Using these molecular genetic strategies to investigate the impact of natural genetic variation on vascular matrix remodeling has begun to shed new light on the importance of these genes in atherogenesis.
Henney
A M
AM
King Gustav Vth Research Institute, Karolinska Institute, Stockholm, Sweden. adriano.henney@astrazeneca.com
Ye
S
S
Zhang
B
B
Jormsjö
S
S
Whatling
C
C
Eriksson
P
P
Hamsten
A
A
D001161:Arteriosclerosis / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology*; D002874:Chromosome Mapping; D002877:Chromosomes, Human; D018450:Disease Progression; D014644:Genetic Variation; D006801:Humans; D020782:Matrix Metalloproteinases / Q000235:genetics* / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000235:genetics
D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases